Biologics / Biotechnology

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biologics / Biotechnology #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #In Silico Biology #Lead discovery #Metabolomics #Molecular medicine #Oncology #PCR #Pharmacology #Precision medicine #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

Predictive safety & research methods: The keys to precision medicine?

Could The Keys To Precision & Personalised Medicine Be Rooted In Predictive Safety & Research Methods? By Robert G. Hunter To meet the massive challenges of future healthcare, perhaps no two facets hold greater promise than biomarkers for precision medicine and systems biology for personalised patient care. Although a high… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Animal models #Biologics / Biotechnology #Cell therapy #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Gene therapy #Immunology #Lead discovery #Lead optimisation #Oncology #Pharmacology #Pharmokinetics #Protein chemistry / Proteomics #RNA #Stem cells #Therapeutics #Toxicology

Long Live Peptides – Evolution of peptide half-life extension technologies and emerging hybrid approaches

Long Live Peptides - Evolution of peptide half-life extension technologies and emerging hybrid approaches By Dr Ronald V. Swanson Among therapeutic modalities, peptides occupy a middle ground between traditional ‘small molecule’ drugs and the larger injectable biologics, not fitting comfortably into either category. Peptides, particularly those based on endogenous human… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biologics / Biotechnology #Business #Cell culture #Cellular assays #Chemistry #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #High Content Screening #High throughput screening #Imaging #Immunology #In Silico Biology #Lead discovery #Lead optimisation #Oncology #Pharmacology #Preclinical #RNA #Screening #System biology #Systems biology #Target validation

The Current Status of Non-Biopharma Drug Discovery

The Current Status of Non-Biopharma Drug Discovery By Dr John Comley Screening centres in academic institutions and non-profit organisations have, over the past decade, become an established mechanism to exploit novel targets and neglected diseases and to identify chemical probes. Where centres have a disease focus, their main expertise resides… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biologics / Biotechnology #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Enabling technologies #Flow Cytometry #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Medicinal chemistry #Molecular medicine #Oncology #Pathology #Pharmacology #Protein chemistry / Proteomics #Regenerative Medicine #RNA #Screening #Stem cells #System biology #Systems biology #Therapeutics #Toxicology #Translational #Translational chemistry

Large-Scale Expansion of Stem Cells For Therapy and Screening

Large-Scale Expansion of Stem Cells For Therapy and Screening By Dr Y. John Shyu, Dr Katherine E. Strathearn and Dr Richard M. Eglen Recently, pre-clinical and clinical studies of stem cells in regenerative medicine have demonstrated great promise as treatments for various diseases. Their ability to self-renew and differentiate makes… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biologics / Biotechnology #Biomarkers #Business #Cell therapy #Cellular assays #Chemical engineering #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug repositioning #Drug targets #Gene therapy #Lead discovery #Microbiology #Orphan drugs #Preclinical #Regulatory #RNA #Sequencing #System biology #Systems biology #Therapeutics #Translational #Translational chemistry

The Drug Repositioning Revolution: Rescuing & Repurposing Drugs

The Drug Repositioning Revolution: Rescuing & Repurposing Drugs By Dr Monika Green and Dr Kate Hudson-Farmer Cost containment and improving ways of treating people are key drivers for healthcare systems. Unfortunately, these do not often go hand in hand. Finding novel therapeutics with enhanced efficacy is both time consuming and… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Automation / robotics #Biologics / Biotechnology #Business #Cell culture #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Immunology / Virology & Vaccines #Protein chemistry / Proteomics #Regenerative Medicine #RNA #Screening #Sequencing #Stem cells #Target validation #Translational #Translational chemistry

Diverging Paths, Difficult Choices – Challenges Facing Pharma

Diverging Paths, Difficult Choices - Challenges Facing Pharma By Dr Steve Arlington and Dr Nick Davies Pharma is poised on a knife-edge. Major scientific and technological advances, together with socio-demographic changes, rising demand for medicines and trade liberalisation, will revive its fortunes in another decade. But in the meantime it… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biologics / Biotechnology #Biomarkers #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #High Content Screening #High throughput screening #Lead discovery #Oncology #Pathology #Pharmacology #Pharmokinetics #Preclinical #RNA #Screening #Stem cells #Target validation #Therapeutics #Translational #Translational chemistry

Asian Innovation: A Unique Opportunity For The Pharmaceutical Industry

Asian Innovation: A Unique Opportunity For The Pharmaceutical Industry By Dr Yi Gu and William Shi As the third-largest market for the pharmaceutical industry, the China/Asia region is becoming increasingly important. The AstraZeneca Innovation Center China (ICC) in Shanghai is perfectly positioned to benefit from close proximity to key opinion… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biobanking #Biologics / Biotechnology #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Enabling technologies #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Medicinal chemistry #Metabolomics #Molecular medicine #Oncology #Patent Law #Precision medicine #Regulatory #RNA #Screening #Sequencing #System biology #Systems biology #Target validation #Therapeutics #Translational #Translational chemistry

The Information Symphony: Data orchestration for a changing industry managing data on a platform for innovation.

The Information Symphony: Data orchestration for a changing industry managing data on a platform for innovation. By Chris Molloy A leading ballet conductor (1) recently told me of courses which he runs for senior business leaders. He allows them to conduct an orchestra: first, very strictly, with close direction applied… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Biologics / Biotechnology #Biomarkers #Business #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #High Content Screening #Imaging #Immunology #Oncology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #Target validation #Therapeutics #Toxicology

Current and Emerging Trends In Immunogenicity Research

Current and Emerging Trends In Immunogenicity Research In November 2011 Drug Discovery World hosted a collegial style roundtable discussion on the present and emerging developments in this fundamental area of drug discovery and development. The participants are drawn from the biopharmaceutical, biotechnology and vendor community. Although somewhat sketchy in places… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biologics / Biotechnology #Business #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Genomics #High Content Screening #Immunology #Lead discovery #Pharmacology #Preclinical #RNA #Screening #System biology #Systems biology #Toxicology #Translational #Translational chemistry

From Outsourced To Open: The continuing evolution of the drug discovery business model

From Outsourced To Open: The continuing evolution of the drug discovery business model Dr Mary Canady One doesn't have to look far to find that the large pharmaceutical business model has many market forces working against it, such as patent expirations, dwindling pipelines, and reduced R&D productivity. However, these factors… Read More

#Archive

#AI / data analytics / healthtech / informatics #Animal models #Assay development optimisation & technology #Automation / robotics #Biologics / Biotechnology #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #High throughput screening #Immunology #Immunology / Virology & Vaccines #Lead discovery #Lead optimisation #Protein chemistry / Proteomics #Regenerative Medicine #RNA #Screening #Stem cells #System biology #Systems biology #Therapeutics #Toxicology #Translational #Translational chemistry

Stem Cell Technology – Delivering the promise

By Dr Aaron Heifetz The promise of stem cell technology as a tool for drug discovery, drug development and as a therapeutic modality is no longer in the future but part of contemporary healthcare. The speed which stem cells have been integrated into biomedical product development has surprised many, but… Read More

#Archive

#Analysis #Animal models #Assay development optimisation & technology #Biologics / Biotechnology #Business #Cell therapy #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Enabling technologies #Gene therapy #High Content Screening #Lead discovery #Oncology #Patent Law #Regenerative Medicine #Regulatory #RNA #Screening #Stem cells

Regenerative Medicines: A Paradigm Shift in Healthcare

By Michael Werner, Morrie Ruffin and Elizabeth West The regenerative medicine market offers phenomenal opportunities for growth in the next few decades. However, there are still major issues to be addressed to enable this nascent industry to truly flourish, especially with regard to investment and the attitudes of regulatory agencies… Read More

#Archive

#AI / data analytics / healthtech / informatics #Animal models #Assay development optimisation & technology #Biochemistry #Biologics / Biotechnology #Business #Cell therapy #Cellular assays #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug repositioning #Drug targets #Gene therapy #High Content Screening #Immunology #Lead discovery #Mass spectrometry / NMR #PCR #Pharmokinetics #Preclinical #RNA #Screening #Stem cells #System biology

The Benefits Of Drug Repositioning

The Benefits Of Drug Repositioning By Dr Aris Persidis Drugs in development, on the market, or those that are shelved because of lack of efficacy, are excellent starting points for further development. Finding new indications for such drugs will benefit patients who will see a potential new therapy sooner, will… Read More

#Archive

#Automation / robotics #Biologics / Biotechnology #Business #Cell therapy #Cellular & Molecular biology #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Immunology #Lead discovery #Oncology #Pharmokinetics #Regulatory #RNA

Balancing A Biologics Pipeline Portfolio

Balancing A Biologics Pipeline Portfolio By Dr Herren Wu Research into groundbreaking biologic therapies has significantly shifted the diagnosis and treatment paradigms for many disease categories, particularly in oncology, autoimmune, inflammation and neurology. Discovering and developing an innovative, first-in-class biologic has the potential to offer patients significant benefits as well… Read More

#Archive

#AI / data analytics / healthtech / informatics #Biologics / Biotechnology #Business #Cell culture #Clinical trials #Drug development #Drug discovery #High Content Screening #Lead discovery #Preclinical #Regulatory #RNA

R&D Open Verdict?

R&D Open Verdict? By Dr Kay Wardle As pharmaceutical companies begin to shift from in-house R&D to external partnerships and 'open innovation', the traditional drug discovery model may soon be a thing of the past. In this article we explain what is driving these changes and what the implications are… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Biologics / Biotechnology #Cell therapy #Clinical specialities #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #High throughput screening #Immunology #Oncology #PCR #Preclinical #RNA #Screening #Stem cells #Therapeutics #Toxicology

New Ways to Optimise Therapeutic and Diagnostic Antibodies

New Ways to Optimise Therapeutic and Diagnostic Antibodies By Dr Markus Enzelberger Monoclonal antibodies are the fastest-growing category of research within the biotech and pharmaceutical industries. Several monoclonal antibodies are listed in the top 10 selling blockbusters, and the market forecast predicts that the number of monoclonal antibodies within the… Read More

#Archive